All In Biotech

Drug Trial Radar · NCT07635394

Efficacy of Pregabalin for Patients With Irritable Bowel Syndrome

Efficacy and Safety of Pregabalin in Patients With Irritable Bowel Syndrome : A Multi-center Prospective Randomized Open Blinded End-point Trial

Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 258 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

258

Planned (sponsor's estimate)

Start

Apr 7, 2026

Primary completion

Apr 8, 2026

Study completion Mar 31, 2029

Sponsor

Lead sponsor
Beijing Tiantan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hengshui People's Hospital; Hebei Medical University Third Hospital; Beijing Rehabilitation Hospital
First posted
Jun 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To explore the efficacy of pregabalin for patients with irritable bowel syndrome (IBS).

Conditions

  • Irritable Bowel Syndrome (IBS)

Interventions

  • The pregabalin groupDrug

    75 mg twice daily for 3 days, followed by 150 mg twice daily for 3 days during the first week; 225 mg twice daily at week 10; and a tapering regimen at week 12 (150 mg twice daily for 3 days, then 75 mg twice daily for 3 days).

  • Routine TreatmentDrug

    Patients also received routine treatment from gastroenterologists. Loperamide: 2-4 mg after each loose stool (max 16 mg/day) to reduce stool frequency, though it does not relieve pain. Rifaximin: 550 mg TID for 14 days (repeatable); or Eluxadoline 100 mg BID (75 mg BID in post-cholecystectomy patients), which is contraindicated in pancreatitis or biliary obstruction. Antispasmodics: Dicyclomine: 10-20 mg QID or Hyoscyamine as needed for cramping.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The IBS Severity Scoring System (IBS-SSS) and respnse rateTime frame: Up to 12 weeks after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.